10-Q · May 14, 2026
Cypherpunk Technologies has reported a significant reduction in operating expenses and a drastic drop in net loss for Q1 2026 compared to the previous year. The company continues to invest heavily in its digital asset…
Earnings analysis · 10-Q
CYPH earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the statements of operations, balance sheet, cash flow statement, or MD&A financial data, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance…
Read full summary
The supplied 10-Q extract does not include the statements of operations, balance sheet, cash flow statement, or MD&A financial data, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be quantified. The principal disclosed development is that the material weakness identified in the March 16, 2026 Form 10-K remained unremediated as of June 30, 2026, resulting in ineffective disclosure controls. Management is implementing remediation, but provided no quantitative forward guidance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Remediation plan underway
Management continued its remediation plan as of June 30, 2026, including additional training, control improvements, and the engagement of third-party technical accounting resources.
-
No legal or insider-trading actions
The filing reported no legal proceedings under Item 1 and no director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
What to watch
-
Unremediated control weakness
The material weakness in internal control over financial reporting identified in the March 16, 2026 Form 10-K remained unremediated as of June 30, 2026. Management therefore concluded that disclosure controls and procedures were not effective at that date.
-
Management role concentration
The CEO also serves as CFO and principal financial officer as of June 30, 2026, concentrating the principal executive and financial officer roles in one individual.
-
Remediation timing remains uncertain
The filing states that remediation will not be considered complete until controls have operated for a sufficient period and management has concluded through testing that they are effective, leaving the timing of remediation uncertain as of June 30, 2026.
Management's outlook
No quantitative forward guidance or outlook was provided in the supplied 10-Q extract.
Earlier filings 4
10-K · March 16, 2026
Cypherpunk pivoted from a pure biotechnology company to a privacy-technology and digital-asset treasury strategy anchored in Zcash (ZEC), following a $58.88 million private placement in October 2025. As of March 11,…
10-Q · August 14, 2025
Leap Therapeutics reported no product revenue and continues to operate at a loss. For the six months ended June 30, 2025 the company incurred a net loss of $32.1 million and had cash and cash equivalents of $18.1…
10-Q · August 12, 2024
Leap Therapeutics reported no revenue and a net loss of $20.128 million for the three months ended June 30, 2024, driven by higher R&D activity as the company advances DKN-01. The company completed a $40.0 million…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.